1Bell R, Verma S, Untch M, et al. Maxizing clinical benefit with trastuzumab. Semin Oncol, 2004, 31:35-44.
2Slamon DJ, Leyland - Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344: 783- 792.
3Bangemann N, Kuhle A, Ebert A, et al. Capecitabine combined with trastu.zurnab in the therapy of intensive pretreated HER2 -overexpressing metastatic breast cancer. Proc Eur Soc Clin Oncol,2000, 11:143 (abstr653P).
4Hones A, Leyland- Jones B. Optimizing treatment of HER2 -positive metastatic breast cancer. Semin Onool, 2004, 31 (Supp110): 29-34.
5Heodoulou M, Carnpos S, Batist G, et al. TLC 1399 and Herceptin (H) is safe in advanced breast cancer (ABC) : final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol, 2002, 21 :55a (abstr 216).
6Lai R, Dang CT, Malkin MG, et al. The risk of central nervous system metastases after Trastuzumab therapy in patients with breast carcinoma. Cancer, 2004, 101:810-816.
